Latest From Biotech Now

Exclusive Licenses Do Not Discourage Follow On Research

medical_research_thumb

A recent study presented at the Patent Statistics for Decision Makers Conference organized at the United States Patent Office questions the logic behind a nonexclusive license preference often found in U.S. government technology transfer policy. In “The Role of Exclusive Licensing in Follow-on Research of Academic Patented Inventions” presentation the authors demonstrate that, contrary to the belief by some, exclusive licensing does not impede future research. The authors ask two questions.  First, does exclusive licensing affect licensee follow-on research?  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

15 Keys to Success from Fierce Biotech’s Top 15 Women in Biotech

lab_tech

This week, Fierce Biotech recognized 15 women who are leading the way in biotech. Each of them represents the drive and determination that it takes to succeed in the industry, but what do they recommend beyond these inherent qualities? We pulled together the list below based on their profiles so that others can learn from their experience (yes, that made the list). In no particular order: 1. Take risks 2. Have an entrepreneurial spirit 3. Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: ,

NIH: Streamlining the Technology Transfer Process

cyclotron

The National Institutes of Health (NIH) is launching the electronic Research Materials catalogue (eRMa) to streamline the federal government’s technology transfer process. “To stay competitive in today’s world, on-line ordering is a requirement. With the launch of this first-of-its kind system, OTT is demonstrating its intention to meet that challenge,” said Mark Rohrbaugh, director of OTT. According to the press release: “The new system will streamline the licensing process by: Providing a website for companies Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , ,

Future Requires Both Innovation and Collaboration

Paul Schickler DuPont

The Wilmington News Journal’s recent article, “GMOs: 10 Simple Questions (and Some Surprising Answers)” garnered a lot of attention on both sides of the debate around biotech foods.  Among the responses, a thoughtful piece authored by Pioneer Hi-Bred president Paul Schickler was published in the paper’s Sunday edition: Biotech crops are perhaps the most stringently regulated aspect of agriculture – held to the highest level of analysis and scrutiny. They are regulated by three federal Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Podcast: Ethics of Global Clinical Trials

Dr. Russell Medford

Holland & Knight’s Michael Werner talks to Dr. Russell Medford, President and CEO of Salutria Pharmaceuticals, a privately-held biotech company based in Alpharetta Georgia. Dr. Medford is also co-chair of BIO’s Board Standing Committee on Bioethics. Dr. Medford will be providing testimony on Wednesday November 16 to the Presidential Commission for the Study of Bioethical Issues on Principles Regarding Ethical Performance of International Clinical Trials.

Health  |  Leave a comment  |  Email This Post